StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $0.70 on Wednesday. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $9.35. The stock’s 50 day simple moving average is $2.01 and its 200 day simple moving average is $3.72.

Institutional Trading of Eagle Pharmaceuticals

Large investors have recently modified their holdings of the business. Headlands Technologies LLC lifted its holdings in Eagle Pharmaceuticals by 75.7% in the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares during the period. Creative Planning bought a new position in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $59,000. Mackenzie Financial Corp purchased a new stake in Eagle Pharmaceuticals in the second quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eagle Pharmaceuticals in the second quarter worth $65,000. Finally, Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the second quarter valued at $71,000. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.